An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs - PubMed
7 hours ago
- #EGFR
- #glioblastoma
- #lncRNA
- A lncRNA named HELDR is co-amplified with EGFR in glioblastoma (GBM) and promotes tumor malignancy independently of EGFR signaling.
- HELDR recruits p300 to the KAT7 promoter, increasing H3K27ac and activating KAT7 transcription, which in turn drives gene programs critical for GBM through histone acetylation (H3K14ac and H4K12ac).
- Targeting HELDR or KAT7 enhances the therapeutic effects of anti-EGFR treatments in GBM, suggesting new strategies for cancer therapy.